陈玲, 李旭. 肺癌多药耐药机制及逆转研究[J]. 实用临床医药杂志, 2005, (11): 34-37. DOI: 10.3969/j.issn.1672-2353.2005.11.010
引用本文: 陈玲, 李旭. 肺癌多药耐药机制及逆转研究[J]. 实用临床医药杂志, 2005, (11): 34-37. DOI: 10.3969/j.issn.1672-2353.2005.11.010
CHEN Ling, LI Xu. Study on mechanism of lung cancer′s multidrug resistance and its reversion[J]. Journal of Clinical Medicine in Practice, 2005, (11): 34-37. DOI: 10.3969/j.issn.1672-2353.2005.11.010
Citation: CHEN Ling, LI Xu. Study on mechanism of lung cancer′s multidrug resistance and its reversion[J]. Journal of Clinical Medicine in Practice, 2005, (11): 34-37. DOI: 10.3969/j.issn.1672-2353.2005.11.010

肺癌多药耐药机制及逆转研究

Study on mechanism of lung cancer′s multidrug resistance and its reversion

  • 摘要: 耐药性是化疗失败的主要原因之一,存在于化疗之前即内原性耐药,在化疗中产生即为获得性耐药1.多药耐药性(Multidrug Resistance, MDR)是指细胞在接触一种抗癌药物后产生了对其他多种结构与功能迥异的天然抗癌药物的耐药性2, 肺癌的多药耐药性,具有其特殊性,被从实验和临床多个角度对肺癌的耐药性进行了广泛而深入地研究.

     

/

返回文章
返回